Peter Kok-Ting Wan, Gulsah Albayrak, Puck E Bruchner, Shuangye Yan, Luke Furtado O'Mahony, Kerry D Fisher, Leonard W Seymour
{"title":"Lipid-rich ascites reprograms the T cell lipid metabolic transcriptome to drive dysfunction.","authors":"Peter Kok-Ting Wan, Gulsah Albayrak, Puck E Bruchner, Shuangye Yan, Luke Furtado O'Mahony, Kerry D Fisher, Leonard W Seymour","doi":"10.1158/2326-6066.CIR-26-0206","DOIUrl":"https://doi.org/10.1158/2326-6066.CIR-26-0206","url":null,"abstract":"<p><p>Malignant ascites is a lipid-rich, immunosuppressive environment that has recently emerged as a target for locoregional bispecific T-cell engager (BiTE) therapy. However, the mechanisms by which ascites, particularly its lipid components, suppress antitumour immunity and limit therapeutic efficacy remain poorly understood. Here, we investigated the impact of ascites lipids on T-cell immunosuppression and assessed whether lipid modulation could enhance the efficacy of BiTE therapy. Transcriptomic profiling of T cells exposed to acellular ascites fluid revealed an enriched signature associated with cholesterol efflux and incomplete fatty acid oxidation, which are metabolic features often found in exhausted T cells. These alterations converged on a metabolically imbalanced state linked to impaired plasma membrane signalling. Meanwhile, anti-CD3/CD28-stimulated T cells showed marked lipid accumulation in ascites, which was attenuated by lipid depletion. Functionally, lipid removal was associated with enhanced TCR-associated signalling, as demonstrated by increased ZAP70 phosphorylation, and restored CD137 expression while leaving CD25 unchanged. To determine whether ascites lipids also affected BiTE efficacy, T cells were cocultured with ovarian cancer cells and an EpCAM-targeting BiTE in untreated or lipid-depleted ascites. Ascites suppressed BiTE-mediated T-cell activation and abolished tumour cell killing, whereas lipid depletion contributed to the restoration of T-cell activation, IFN-γ production and BiTE-mediated cytotoxicity. Together, these findings suggest that lipids contribute to T-cell dysfunction in ovarian cancer ascites and demonstrate that lipid depletion is associated with restored antitumour T-cell activity. Targeting this metabolic barrier may therefore provide a combination strategy to potentiate BiTE therapy in malignant ascites.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stephanie Solis, Asa A Brockman, Claire E Cross, Madeline J Grider-Hayes, Christopher S Jetter, Nicholas M Negretti, Bret C Mobley, Akshitkumar Mistry, Silky Chotai, Kyle D Weaver, Reid C Thompson, Lola B Chambless, Jennifer M S Sucre, Rebecca A Ihrie, Jonathan M Irish
{"title":"IL-8 in Human Glioblastoma Tumors Instructs Immunosuppressive Myeloid Cells.","authors":"Stephanie Solis, Asa A Brockman, Claire E Cross, Madeline J Grider-Hayes, Christopher S Jetter, Nicholas M Negretti, Bret C Mobley, Akshitkumar Mistry, Silky Chotai, Kyle D Weaver, Reid C Thompson, Lola B Chambless, Jennifer M S Sucre, Rebecca A Ihrie, Jonathan M Irish","doi":"10.1158/2326-6066.CIR-26-0415","DOIUrl":"10.1158/2326-6066.CIR-26-0415","url":null,"abstract":"<p><p>Adult glioblastoma (GBM) is an aggressive brain tumor that has yet to benefit from advances in immunotherapy. Prior studies report contrasting leukocyte immunophenotypes between tumors and an association between myeloid macrophage infiltration and worse patient outcomes. IL-8, a cytokine with both inflammatory and suppressive roles, was recently associated with M2 macrophage phenotypes in GBM. These observations raise key questions: do GBM macrophages suppress or support other immune cells, is IL-8 in GBM a mechanistic driver of GBM macrophage function, and can IL-8 instruct macrophages in situ within tumors? Here, functional experiments with primary human GBM tumor cells from initial surgical resections showed that IL-8 from GBM contributes to and is sufficient to instruct monocyte-derived macrophages that suppress healthy T cells. Notably, IL-8 protein expression was enriched in aggressive tumors contacting the V-SVZ region and was not associated with increased infiltration of cells expressing the IL-8 receptors CXCR1/CXCR2. Suppressor cells instructed by GBM ex vivo phenotypically matched myeloid macrophages observed in vivo, and neutralizing IL-8 during instruction blocked this and restored T cell proliferation. Analysis of IL-8 RNA showed the cytokine is primarily produced by CD45- tumor cells. These results suggest a model where ongoing IL-8 production by GBM cells maintains an immunosuppressive microenvironment by signaling to myeloid macrophages within the tumor. Immunotherapies relying on T cells should now investigate whether IL-8 blockade prevents instruction of macrophages into tumor-protective suppressor cells.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"MicroRNA core machinery maintains mitochondrial integrity to empower cancer escape from natural killer cell cytotoxicity.","authors":"Jun-Yi Chen, Ze-Fang Zhao, Hai-Xin Zhao, Miaowen Zou, Chuhan Joyce Qi, Zhen-Gang Peng, Tian-Yu Song, Yong Cang","doi":"10.1158/2326-6066.CIR-26-0559","DOIUrl":"https://doi.org/10.1158/2326-6066.CIR-26-0559","url":null,"abstract":"<p><p>Natural killer (NK) cells offer a promising off-the-shelf platform for cancer immunotherapy, yet their clinical efficacy is often limited by tumor-intrinsic resistance. Here, we show that loss of core microRNA (miRNA) machinery components, Argonaute‑2 (AGO2) or Ankyrin Repeat Domain 52 (ANKRD52), renders tumor cells hypersensitive to NK cell-mediated killing in both co-culture and xenograft models. Mechanistically, genetic ablation of Ago2 or Ankrd52 impairs miRNA-mediated silencing of critical mitochondrial apoptotic regulators and NK-cell-associated ligands in tumor cells, exemplified by the disrupted repression of pro-apoptotic Bim transcripts by miR-24 and miR-29b, thereby unleashing rapid TNF-α-driven apoptosis. Additionally, metabolic and ultrastructural analyses demonstrate collapsed membrane potential, diminished ATP levels, and fragmented mitochondria in Ago2- or Ankrd52-mutant tumor cells, accompanied by a lower apoptotic threshold upon TNF-α or NK cell challenge. Genome‑wide CRISPR library screen further revealed a selective fitness dependency on mitochondrial electron‑transport and ATP‑synthase genes in mutant tumor cells. Collectively, these findings define defective miRNA machinery as a tumor‑intrinsic vulnerability that couples mitochondrial fragility with increased NK-mediated cytotoxicity, nominate miRNA‑pathway status as a predictive biomarker, and propose that co‑targeting mitochondrial metabolism or apoptosis may potentiate NK‑cell therapies.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yan-Ruide Li, Yichen Zhu, Yanqi Yu, Adam Kramer, Zhengyao Shao, Yuning Chen, Xinyuan Shen, Catherine Zhang, Nathan Ma, Annabel Zhao, Christopher J Ochoa, Gabriella A DiBernardo, Thomas Yuen, Coral L Clune, Paulina Dominguez-Vela, Shelby Yeh, Zhaojun Qiu, Jie Huang, Arnold I Chin, Sarah M Larson, Caspian Oliai, Sanaz Memarzadeh, Lili Yang
{"title":"Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy.","authors":"Yan-Ruide Li, Yichen Zhu, Yanqi Yu, Adam Kramer, Zhengyao Shao, Yuning Chen, Xinyuan Shen, Catherine Zhang, Nathan Ma, Annabel Zhao, Christopher J Ochoa, Gabriella A DiBernardo, Thomas Yuen, Coral L Clune, Paulina Dominguez-Vela, Shelby Yeh, Zhaojun Qiu, Jie Huang, Arnold I Chin, Sarah M Larson, Caspian Oliai, Sanaz Memarzadeh, Lili Yang","doi":"10.1158/2326-6066.CIR-26-0767","DOIUrl":"https://doi.org/10.1158/2326-6066.CIR-26-0767","url":null,"abstract":"<p><p>Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is often limited by insufficient antibody-dependent cellular cytotoxicity (ADCC), tumor antigen escape, and an immunosuppressive tumor microenvironment (TME). To overcome these limitations, we developed an allogeneic stem cell-derived invariant natural killer T (NKT) cell platform engineered to express a high-affinity non-cleavable CD16 receptor (CD16HSC-NKT) for broad enhancement of mAb-based immunotherapy. Using a clinically guided differentiation platform, we generated highly pure and scalable CD16HSC-NKT cells exhibiting robust expression of NK receptors, potent cytotoxic machinery, and a Th1-biased cytokine profile. CD16HSC-NKT cells demonstrated potent intrinsic antitumor activity and potently enhanced the efficacy of multiple therapeutic antibodies, including Trastuzumab, Tafasitamab, Rituximab, Daratumumab, and Cusatuzumab, across diverse hematologic and solid tumor models. In vivo, combination therapy induced durable tumor eradication and prolonged survival in xenograft models, outperforming the clinically approved antibody-drug conjugate trastuzumab deruxtecan. Mechanistically, therapeutic antibodies promoted the expansion, persistence, and activation of CD16HSC-NKT cells within tumors. CD16HSC-NKT uniquely remodeled the TME by selectively depleting CD1d-expressing tumor-associated macrophages and myeloid-derived suppressor cells. CD16HSC-NKT cells also exhibited minimal alloreactivity, no graft-versus-host disease, and no detectable systemic toxicity. Collectively, these findings establish CD16HSC-NKT cells as a safe, off-the-shelf cellular platform capable of broadly enhancing monoclonal antibody therapy through sustained ADCC, multimodal tumor targeting, and TME remodeling.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Margaret M Blythe, Christian J Yee, Tejashri Jadhav, Jared L Dietze, Hannah A Miller, Maria C Massaro, Sebastian Newrzela, Marit M van Buuren, Gavin M Palowitch, Charles L Dulberger, John R Srouji, Richard B Gaynor, Vikram R Juneja, Kendra C Foley
{"title":"A Library of Potent TCRs Derived from Healthy Donors Targeting Kras G12d and G12v Neoantigens.","authors":"Margaret M Blythe, Christian J Yee, Tejashri Jadhav, Jared L Dietze, Hannah A Miller, Maria C Massaro, Sebastian Newrzela, Marit M van Buuren, Gavin M Palowitch, Charles L Dulberger, John R Srouji, Richard B Gaynor, Vikram R Juneja, Kendra C Foley","doi":"10.1158/2326-6066.CIR-26-0724","DOIUrl":"https://doi.org/10.1158/2326-6066.CIR-26-0724","url":null,"abstract":"<p><p>Kirsten rat sarcoma (KRAS), the most frequently altered oncogene, is a key target for T cell-based therapies. Mutant KRAS (mKRAS)-specific T cell receptors (TCRs) enable targeted treatment for patients with matching mKRAS/HLA allele pairs. We generated a TCR warehouse library covering approximately one-quarter of pancreatic ductal adenocarcinoma patients and 10% of colorectal cancer patients. Warehouse TCRs exhibit strong avidities and cytotoxicity, comparable to existing benchmark TCRs. Detailed characterization of each TCR revealed unique biology for specific KRAS neoantigens. TCRs with high sensitivity for KRAS G12V/HLA-C*01:02 also recognize the wild-type epitope. However, the wild-type epitope abundance appears to be significantly lower, potentially creating a therapeutic window, albeit necessitating deeper evaluation. Additionally, we show that TCRs recognize KRAS G12V on HLA-C*03:03 and HLA-C*03:04 interchangeably, thereby resulting in a single neoantigen with one of the highest frequencies. In summary, this mKRAS-targeted TCR library comprises candidates for further preclinical and clinical development.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Houyu Ju, Yusheng Lu, Chaoji Shi, Zhiwei Zheng, Yun Bi, Wenyi Yang, Zhaoyang Guo, Mahdi D Dashti, Ming Yan, Guoxin Ren, Jingzhou Hu
{"title":"CD266+ Myofibroblasts Mediate Resistance to Immunochemotherapy through ECM Stiffness in Head and Neck Squamous Cell Carcinoma.","authors":"Houyu Ju, Yusheng Lu, Chaoji Shi, Zhiwei Zheng, Yun Bi, Wenyi Yang, Zhaoyang Guo, Mahdi D Dashti, Ming Yan, Guoxin Ren, Jingzhou Hu","doi":"10.1158/2326-6066.CIR-25-1379","DOIUrl":"10.1158/2326-6066.CIR-25-1379","url":null,"abstract":"<p><p>The efficacy of immunotherapy in unresectable/recurrent/metastatic head and neck squamous cell carcinoma (U/R/M HNSCC) remains suboptimal compared with primary untreated resectable HNSCC. The immunologic and stromal landscape during immunotherapy in U/R/M HNSCC is crucial for understanding drug resistance mechanisms. In this study, single-cell RNA sequencing was performed on 42 pre- and posttreatment samples from patients in our prospective trial (NCT05156970) who received immunochemotherapy. A subset of myofibroblasts expressing CD266 was identified as hampering the response to immunochemotherapy in patients with U/R/M HNSCC. This distinct subtype of cancer-associated fibroblasts (CAF) enhanced extracellular matrix (ECM) stiffness and cellular tension through a PIEZO1-mediated biomechanical mechanism, spatially segregated CD8+ T-cell infiltration to establish immune-excluded niches, and ultimately facilitated immune evasion. Mechanistically, PIEZO1 inhibition suppressed YAP activation and reduced FAK phosphorylation, thereby mitigating matrix remodeling effects driven by myofibroblastic CAF CD266. We also observed that PIEZO1 inhibition had a synergistic effect with PD-1 blockade in HNSCC in vivo. In summary, our findings reveal an immunosuppressive mechanism in which stromal cells regulate ECM stiffness, presenting a potential therapeutic target for U/R/M HNSCC.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":"1782-1800"},"PeriodicalIF":7.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sophia Corbo, Khalid N M Abdelazeem, Diemmy Nguyen, Shilpa Bhatia, Benjamin Van Court, Nicholas A Olimpo, Jacob Gadwa, Chloe A Hodgson, Jessica I Beynor, Von G Samedi, Enrique Sanz-Garcia, Lillian L Siu, Anthony J Saviola, Lynn E Heasley, Elena B Pasquale, Michael W Knitz, Sana D Karam
{"title":"EphA4 Mediates Protumoral and Antitumoral Effects through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma.","authors":"Sophia Corbo, Khalid N M Abdelazeem, Diemmy Nguyen, Shilpa Bhatia, Benjamin Van Court, Nicholas A Olimpo, Jacob Gadwa, Chloe A Hodgson, Jessica I Beynor, Von G Samedi, Enrique Sanz-Garcia, Lillian L Siu, Anthony J Saviola, Lynn E Heasley, Elena B Pasquale, Michael W Knitz, Sana D Karam","doi":"10.1158/2326-6066.CIR-25-1353","DOIUrl":"10.1158/2326-6066.CIR-25-1353","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is driven by an immunosuppressive tumor microenvironment (TME). We examined the immunomodulatory role of EphA4 in HNSCC using spatial analysis, multicompartment RNA sequencing from oral cavity squamous cell carcinoma, and three genetically engineered mouse models. Within the HNSCC TME, EphA4 is primarily expressed in regulatory T cells (Treg), macrophages, CD8+ T cells, and HNSCC cancer cells. EphA4 in Tregs promotes tumor growth, whereas EphA4 in myeloid cells, CD8+ T cells, and cancer cells limits it. EphA4 mediates these differential effects through shared negative regulation of AKT signaling where its knockout increases AKT activation, leading to reduced Treg immunosuppression, increased M2 macrophage polarization, impaired CD8+ T-cell memory differentiation, and enhanced cancer cell proliferation. APY-d3-PEG4, an EphA4 inhibitor, reduced tumor growth primarily by targeting Tregs. EphA4 expression on CD8+ T cells correlates with treatment response, representing a potential biomarker, and cell type-specific targeting via cis-bispecific antibodies offers a promising therapeutic strategy. Interrogating human data show that EphA4 expression on CD8 correlates to response to treatment, posing it as a potential biomarker for future studies. Mechanistically, our data show EphA4 inhibits AKT signaling, and its inhibition enhances AKT functionality across cell types, yielding opposing effects in cancer.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":"1801-1825"},"PeriodicalIF":7.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yufeng Guo, Xuezhao Ren, Ze Zhang, Hui Cheng, Jin-Peng Ma, Hong Yan, Qian Niu, Xinyu Zhang, Luyang Zhang, Junqiang Tian, Zhilong Dong, Hanzhang Wang, Liang Cheng, Yong-Jie Lu, Zhiping Wang
{"title":"The Pretreatment Tumor Microenvironment Immune Status Determines Bacillus Calmette-Guerin Immunotherapy Response in Early-Stage Bladder Cancer.","authors":"Yufeng Guo, Xuezhao Ren, Ze Zhang, Hui Cheng, Jin-Peng Ma, Hong Yan, Qian Niu, Xinyu Zhang, Luyang Zhang, Junqiang Tian, Zhilong Dong, Hanzhang Wang, Liang Cheng, Yong-Jie Lu, Zhiping Wang","doi":"10.1158/2326-6066.CIR-25-1445","DOIUrl":"10.1158/2326-6066.CIR-25-1445","url":null,"abstract":"<p><p>Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy for early-stage bladder cancer, based on its immunostimulatory activity. However, more than half of patients experience BCG failure and subsequent recurrence. The heterogeneity of the tumor microenvironment may influence BCG response; however, this relationship is currently not well established. We found that BCG response did not correlate with the number of tumor-infiltrating T cells but was determined by the pretreatment immunosuppressive microenvironment. We identified a subset of cancer-associated fibroblasts characterized by microfibrillar-associated protein 2 (MFAP2+ CAF), which impaired BCG-induced antitumoral immunity by interacting with both individual T cells and tertiary lymphoid structures/lymphoid aggregates. This study also revealed a potential stepwise activation of cancer immune evasion factors based on cross-sectional analysis, from increasing MFAP2+ CAF to activation of programmed cell death ligand 1 and then lymphocyte-activation gene 3 on T cells during early-stage bladder cancer development. These findings have the potential to enable accurate prediction of BCG response. This approach may also be applicable to the investigation of other human cancers.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":"1879-1896"},"PeriodicalIF":7.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mercedes Herrera, Sajid A Marhon, Zhihui Amy Liu, Helen Loo, Farnoosh Abbas-Aghababazadeh, Jeff P Bruce, David Chen, Emily Van de Laar, Helen Chow, Philippe L Bedard, Albiruni R Abdul Razak, Anna Spreafico, Marcus O Butler, Stephanie Lheureux, Trevor J Pugh, Benjamin Haibe-Kains, Lillian L Siu, Daniel D De Carvalho, Pavlina Spiliopoulou
{"title":"Immune Checkpoint Blockade Sensitivity Is Linked to Endogenous Retroelement Transcriptional Changes in Cancer.","authors":"Mercedes Herrera, Sajid A Marhon, Zhihui Amy Liu, Helen Loo, Farnoosh Abbas-Aghababazadeh, Jeff P Bruce, David Chen, Emily Van de Laar, Helen Chow, Philippe L Bedard, Albiruni R Abdul Razak, Anna Spreafico, Marcus O Butler, Stephanie Lheureux, Trevor J Pugh, Benjamin Haibe-Kains, Lillian L Siu, Daniel D De Carvalho, Pavlina Spiliopoulou","doi":"10.1158/2326-6066.CIR-26-0365","DOIUrl":"10.1158/2326-6066.CIR-26-0365","url":null,"abstract":"<p><p>Endogenous retrotransposable elements (ERE) can modulate immune responses. We explored ERE transcription in relation to response to immune checkpoint inhibition in advanced solid tumors. ERE expression was measured in pre- and on-treatment samples from patients treated in a clinical trial with pembrolizumab. We evaluated immune cell infiltration and correlated ERE expression with interferon (IFN)-stimulated gene profiles and cytolytic activity. Two independent datasets were retrospectively analyzed as external validation. ERE transcription, notably Alu repetitive elements followed by long interspersed nuclear elements (LINE), is upregulated in immunotherapy responders, and higher ERE expression correlates with durable clinical benefit and improved long-term outcomes. In responders, this dynamic increase correlates with CD8+ T-cell infiltration and cytolytic activity, particularly during treatment. A trend toward increased A-to-I RNA editing was observed in responders. External validation in melanoma and non-small cell lung cancer cohorts confirmed a consistent pattern in ERE transcription. Therefore, ERE transcription is emerging as a potential biomarker for personalized immunotherapy in solid tumors.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":"1721-1730"},"PeriodicalIF":7.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alex Chen, Jose S Pulido, Jason Tonne, Muriel Metko, Jill M Thompson, Thanich Sangsuwannukul, Maria P Chiriboga-Yerovi, Rosa M Diaz, Mason J Webb, Amanda L Huff, Madelyn Moore, Matthew R Schuelke, Sheeba Irshad, Elizabeth Appleton, Alan Melcher, Benjamin Kendall, Richard G Vile
{"title":"Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.","authors":"Alex Chen, Jose S Pulido, Jason Tonne, Muriel Metko, Jill M Thompson, Thanich Sangsuwannukul, Maria P Chiriboga-Yerovi, Rosa M Diaz, Mason J Webb, Amanda L Huff, Madelyn Moore, Matthew R Schuelke, Sheeba Irshad, Elizabeth Appleton, Alan Melcher, Benjamin Kendall, Richard G Vile","doi":"10.1158/2326-6066.CIR-25-1589","DOIUrl":"10.1158/2326-6066.CIR-25-1589","url":null,"abstract":"<p><p>T-cell immune tolerance is established in part through the activity of the autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTEC) of the thymus. AIRE induces expression of peripheral tissue-specific self-antigens for presentation to naïve T cells to promote activation/deletion of autoreactive T cells. This traditional role of AIRE in mTECs is to prevent autoimmunity. Herein, we demonstrate that tumors mimic the role of AIRE in mTECs to evade immune rejection. We found that AIRE induced a profile of \"selfness\" at the RNA and protein levels which, when presented on major histocompatibility complexes (MHC), shielded the tumor from inherently self-tolerized T cells. Moreover, we describe an in vivo immunotherapy in which engineered changes in AIRE expression in tumor cells altered their profile of selfness, exposing both AIRE-modified and parental unmodified tumor cells to T-cell attack. Therefore, by resetting the immunologic selfness of cancer cells, this AIRE-mediated immunotherapy (i) converted a highly tolerized T-cell compartment into a tumor-reactive T-cell population; (ii) conferred upon nonimmunogenic tumors de novo sensitivity to immune checkpoint blockade; (iii) removed the need to identify potentially immunogenic tumor-associated antigens as targets for generation of T-cell responses; and (iv) lead to potent T cell-mediated rejection of aggressive, immunologically cold, nonimmunogenic tumors. Patient RNA sequencing data showed that the expression of AIRE predicted response to immune therapies with a strong correlation between AIRE expression and markers of T-cell receptor signaling, suggesting that our studies have therapeutic translational value.</p>","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":"1859-1878"},"PeriodicalIF":7.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13737429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}